DA
OVID icon

DCF Advisers’s Ovid Therapeutics OVID Stock Holding History

DCF Advisers’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,750
Closed -$11K – 95
2024
Q4 		$11K Sell
11,750
-3,000
-20% -$3.36K 0.01% 87
2024
Q3 		$17.4K Sell
14,750
-27,000
-65% -$28.2K 0.01% 97
2024
Q2 		$32.1K Buy
41,750
+22,020
+112% +$61.3K 0.02% 91
2024
Q1 		$60.2K Buy
19,730
+1,000
+5% +$3.35K 0.03% 81
2023
Q4 		$60.3K Sell
18,730
-11,700
-38% -$40K 0.03% 78
2023
Q3 		$117K Sell
30,430
-34,334
-53% -$123K 0.06% 88
2023
Q2 		$212K Sell
64,764
-3,500
-5% -$11.9K 0.11% 79
2023
Q1 		$176K Sell
68,264
-2,000
-3% -$4.74K 0.11% 63
2022
Q4 		$131K Sell
70,264
-92,437
-57% -$157K 0.09% 65
2022
Q3 		$299K Buy
162,701
+21,000
+15% +$43.9K 0.19% 62
2022
Q2 		$305K Hold
141,701
– – 0.18% 57
2022
Q1 		$445K Hold
141,701
– – 0.19% 56
2021
Q4 		$455K Hold
141,701
– – 0.18% 59
2021
Q3 		$476K Buy
141,701
+2,000
+1% +$7.29K 0.21% 65
2021
Q2 		$546K Buy
139,701
+30,700
+28% +$121K 0.19% 65
2021
Q1 		$438K Buy
+109,001
New +$362K 0.19% 81

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

DCF Advisers's OVID Position: Q1 2025 in Review

DCF Advisers sold out of Ovid Therapeutics (OVID) in Q1 2025, closing a stake of 11,750 shares — an estimated $11K sold.

DCF Advisers first reported a position in OVID in Q1 2021 and held it in 16 quarters. The position peaked at $546K in Q2 2021. 82 funds tracked by Wall St. Rank hold OVID as of Q1 2025.

  • DCF Advisers reported no remaining Ovid Therapeutics position as of Q1 2025 after selling out during the quarter.
  • DCF Advisers sold 11,750 Ovid Therapeutics shares in Q1 2025, an estimated $11K.
  • DCF Advisers first reported a position in Ovid Therapeutics in Q1 2021 and held it in 16 quarters.
  • DCF Advisers's Ovid Therapeutics position peaked at $546K in Q2 2021.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2025.

Based on DCF Advisers's 13F filing for Q1 2025, filed 9 May 2025.